|Bid||1.4300 x 900|
|Ask||1.4500 x 2900|
|Day's Range||1.4350 - 1.5900|
|52 Week Range||1.1100 - 14.3800|
|Beta (5Y Monthly)||1.81|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 10, 2022 - Aug 15, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||9.33|
Subscribe to Yahoo Finance Plus to view Fair Value for DTIL
Shares of Precision BioSciences (DTIL) are up as the company inks a gene-editing deal with Novartis to develop a potentially curative treatment for disorders like sickle cell disease.
Precision BioSciences is developing gene-editing tools with several potential advantages over Crispr.
A gene editing firm in the Triangle has landed a deal worth up to $1.4 billion with the global pharmaceutical company.